contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


capital-increase-in-bavarian-nordic-as-as-a-result-of-employee-warrant-exercise-10

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S.  Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark. 

Bavarian Nordic

COPENHAGEN, Denmark, September 5, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 7,164,460 as a consequence of employees...

COPENHAGEN, Denmark, September 5, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 7,164,460 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 447,869 shares at DKK 146.60, 7,039 shares at DKK 155.80 and 261,538 shares at DKK 206.82. The total proceeds to Bavarian Nordic A/S from the capital increase amounts to DKK 120.8 million. The new shares, which will rank pari passu in all respects with existing Bavarian Nordic shares, will be admitted to trading and official listing on Nasdaq Copenhagen as soon as possible. After the capital increase, the total nominal value of Bavarian Nordic A/S' share capital is DKK 788,329,820, which is made up of 78,832,982 shares of a nominal value of DKK 10 each, corresponding to 78,832,982 votes. The revised Articles of Association will be published shortly on the Company's website. The content of this announcement does not affect the Company’s expectations for the financial results for 2024. About Bavarian Nordic Bavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, supplied to governments to enhance public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. For more information visit <a href="https://www.globenewswire.com/Tracker?data=JivQD2NQTLUazW6JU-Fv258PEqVsNwnYnSsAKWZPx5-2vCIDRBNIo9DaB-CD-ZvXDmmiHNLf8VWLvXXpKpJme9ltHzsYTRpXznx--AE7Gek=">www.bavarian-nordic.com</a>. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contacts Europe: Rolf Sass Sørensen, Vice President Investor Relations, <a href="https://www.globenewswire.com/Tracker?data=rNqAd2GTRJRBqW1p03p-12WO3cMu-YvnTE3vcEgmGHM2G9hqMGtx2jGEj_GX0f-zC5tTHjbVrTz3yYIEDZDXaFXuvTEkD87ohwDQBQHHLLM=">rss@bavarian-nordic.com</a>, Tel: +45 61 77 47 44 US: Graham Morrell, <a href="https://www.globenewswire.com/Tracker?data=lPP_zeKha_1un6q5I35DaXS7ZEdRnJQTc1Ps0NO05Ki82WkFwRJlDZrHecSSO4ASR6S1zvMp8WsAT9txCnmAvFyons6ReRRaIAbuUc9TxzaQXtBYXUnt0iVTXgYck2Vl">graham@paddockcircle.com</a>, Tel: +1 781 686 9600 Company Announcement no. 27 / 2024 Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/4c5c81d1-41b4-432e-8f22-50b24bde464c">2024-27-en</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMDk5MDExMiM0MDE5Mzk2MjQjMjAwMDUwMg=="> <img src="https://ml-eu.globenewswire.com/media/MjQzNzVjNzMtYTI1Ni00NDFlLWE4MDYtNzJkNWE4NDViMWE4LTEwMTIwNzU=/tiny/Bavarian-Nordic-A-S.png">

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Lääkekehityssijoittaminen: Arvonluonti yrityskaupoilla ja lisensointisopimuksilla

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Pysy ajantasalla Inderesin uutiskirjeillä